Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lysergic acid diethylamide - MindBio Therapeutics

X
Drug Profile

Lysergic acid diethylamide - MindBio Therapeutics

Alternative Names: LSD-MindBio Therapeutics; MB-22001

Latest Information Update: 15 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MindBio Therapeutics
  • Class Analgesics; Antidementias; Antidepressants; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Ergolines; Ergot alkaloids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 02 Jun 2024 Efficacy and adverse events data from a phase IIa trial in Major depressive disorder released by MindBio Therapeutics
  • 14 May 2024 MindBio Therapeutics plans multiple phase IIa/phase IIb trials in women’s health
  • 01 May 2024 MindBio Therapeutics plans a phase III trial for Major depressive disorder in early 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top